股本结构
单位：万股
| 公告日期 | 2024-02-14 | 2023-10-26 | 2023-09-28 | 2023-08-31 | 2023-08-07 | 2023-06-29 |
|---|---|---|---|---|---|---|
| 证券总股本 | 306.95 | 305.67 | 175.04 | 180.00 | 3851.10 | 3704.96 |
| 普通股本 | 306.95 | 305.67 | 175.04 | 180.00 | 3851.10 | 3704.96 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-12-11 | 2023-10-27 | 2023-09-11 | 2023-09-01 | 2023-07-27 | 2023-06-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-02-14 | 306.95 | 未披露 |
更多>>
From October 1, 2023 to December 11, 2023
Sale of common stock, net of issuance costs
Retirement of shares in connection with reverse stock split
Net share settlement of warrants
|
2023-12-11 |
| 2023-10-26 | 305.67 | 未披露 |
更多>>
Common Stock offered 1,306,250 shares by the company
|
2023-10-27 |
| 2023-09-28 | 175.04 | 未披露 | 定期报告 | 2023-09-11 |
| 2023-08-31 | 180.00 | 未披露 |
更多>>
Sonnet BioTherapeutics Holdings, Inc. announced that it will effect a 1-for-22 reverse stock split of its outstanding common stock.
|
2023-09-01 |
| 2023-08-07 | 3851.10 | 未披露 | 定期报告 | 2023-07-27 |
| 2023-06-29 | 3704.96 | 未披露 |
更多>>
Common Stock offered 3,660,000 shares by the company
|
2023-06-30 |
| 2023-06-29 | 3338.96 | 未披露 | 定期报告 | 2023-06-27 |
| 2023-05-10 | 2747.87 | 未披露 | 定期报告 | 2023-05-08 |
| 2023-05-10 | 2049.84 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Sale of common stock, net of issuance costs
Issuance of common stock on vesting of restricted stock units
Net share settlement of warrants
|
2023-03-31 |
| 2023-02-13 | 2023.29 | 未披露 | 定期报告 | 2023-02-10 |
| 2023-02-09 | 2021.99 | 未披露 |
更多>>
Common Stock Offered 11,664,888 shares by the company
|
2023-02-09 |
| 2023-01-30 | 855.50 | 未披露 | 定期报告 | 2023-01-26 |
| 2023-02-13 | 796.40 | 未披露 |
更多>>
From October 1, 2022 to December 31, 2022
Sale of common stock, net of issuance costs
Net share settlement of warrants
|
2022-12-31 |
| 2022-12-15 | 793.42 | 未披露 | 定期报告 | 2022-12-14 |
| 2022-11-09 | 735.49 | 未披露 | 定期报告 | 2022-11-07 |
| 2022-12-15 | 554.45 | 未披露 |
更多>>
From September 30, 2021 to September 30, 2022
Sale of preferred stock and common stock warrants, net of issuance costs
Conversion of preferred stock into common stock
Sale of common stock, net of issuance costs
Issuance of common stock on vesting of restricted stock units
|
2022-09-30 |
| 2022-09-16 | 500.00 | 未披露 |
更多>>
Sonnet BioTherapeutics Holdings, Inc. announced today that it will effect a 1-for-14 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on Monday, September 19, 2022. The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 69.6 million to approximately 5.0 million.
|
2022-09-19 |
| 2022-09-16 | 6960.00 | 未披露 | 定期报告 | 2022-09-16 |
| 2022-08-25 | 6058.79 | 2.25 | 定期报告 | 2022-08-17 |
| 2022-08-15 | 6058.79 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock on vesting of restricted stock units
|
2022-06-30 |
| 2022-05-10 | 6058.79 | 未披露 | 定期报告 | 2022-05-05 |
| 2022-04-12 | 6026.31 | 未披露 | 定期报告 | 2022-04-04 |
| 2022-05-10 | 6026.31 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock on vesting of restricted stock units
|
2022-03-31 |
| 2021-12-17 | 6025.06 | 未披露 |
更多>>
From September 30, 2020 to September 30, 2021
Sale of common stock and warrants, net of issuance costs
Issuance of common stock on vesting of restricted stock units
Net share settlement of warrants
Warrant exercises
|
2021-09-30 |
| 2021-08-24 | 5815.04 | 未披露 |
更多>>
1.Common Stock Offered 33,193,485 shares.
2.The number of shares of common stock that will be outstanding immediately after this offering is based on 24,956,887 shares of common stock outstanding as of August 10, 2021.
|
2021-08-24 |
| 2021-08-16 | 2495.69 | 未披露 | 定期报告 | 2021-08-10 |
| 2021-07-22 | 2475.78 | 未披露 | 定期报告 | 2021-07-07 |
| 2021-05-25 | 2138.83 | 未披露 | 定期报告 | 2021-05-21 |
| 2021-05-17 | 2119.73 | 未披露 |
更多>>
From December 31, 2020 To March 31, 2021
Sale of common stock, net of issuance costs
|
2021-03-31 |
| 2021-02-16 | 1755.59 | 未披露 | 定期报告 | 2021-02-12 |
| 2021-02-16 | 1717.57 | 未披露 |
更多>>
From October 1, 2020 to December 15, 2020
Warrant exercises
Net share settlement of warrants
|
2020-12-15 |
| 2020-12-17 | 1717.57 | 未披露 | 定期报告 | 2020-12-08 |
| 2020-12-17 | 1472.41 | 未披露 |
更多>>
From September 30, 2019 to September 30, 2020
Sale of common stock and warrants, net of issuance costs
Issuance of common stock to settle related-party notes
Issuance of common stock to affect the Relief acquisition
Issuance of common stock and payment made in connection with Merger
Warrant exercises
|
2020-09-30 |
| 2020-08-14 | 1364.40 | 未披露 | 定期报告 | 2020-08-12 |
| 2020-08-14 | 920.02 | 未披露 |
更多>>
from March 31, 2020 to June 30, 2020
Sale of common stock and warrants, net of issuance costs
Issuance of common stock to affect the Relief acquisition
Issuance of common stock and payment made in connection with Merger
|
2020-06-30 |
| 2020-06-26 | 920.16 | 未披露 | 定期报告 | 2020-06-23 |
| 2020-05-18 | 920.02 | 未披露 | 定期报告 | 2020-05-12 |
| 2020-04-22 | 920.16 | 未披露 | 定期报告 | 2020-04-16 |
| 2020-04-03 | 920.00 | 未披露 |
更多>>
In connection with, and immediately prior to the completion of, the Merger, the Company effected a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-26 (the “Reverse Stock Split”).Immediately after the Merger, there were approximately 9.2 million shares of Common Stock outstanding (including 1.1 million Converted Additional Shares (as defined in Item 8.01 of this report) being held in escrow).
|
2020-04-02 |
| 2020-03-19 | 1240.30 | 未披露 | 定期报告 | 2020-03-16 |
| 2020-02-07 | 1117.11 | 未披露 | 定期报告 | 2020-01-31 |
| 2020-03-19 | 1040.43 | 6.29 |
更多>>
from September 30, 2019 to December 31, 2019
Common stock:
Director fees
Preferred Unit dividend
Accrued interest on note payable
Exercise of warrants at reduced price of $0.50
|
2019-12-31 |
| 2019-11-19 | 1025.35 | 未披露 | 定期报告 | 2019-11-13 |
| 2019-11-14 | 1007.35 | 未披露 | 定期报告 | 2019-11-07 |
| 2019-11-14 | 1004.31 | 6.29 |
更多>>
From June 30, 2019 to September 30, 2019
Common stock and warrants issued for:
Preferred Unit dividend
Subscriptions pursuant to rights offering, net
|
2019-09-30 |
| 2019-08-14 | 1004.31 | 未披露 | 定期报告 | 2019-08-06 |
| 2019-08-14 | 701.40 | 6.29 |
更多>>
From March 31, 2019 to June 30, 2019
Common stock and warrants issued for:
Director fees
Consulting services
Preferred Unit dividend
Accrued interest on note payable
Share-based compensation
Stock issued to settle convertible debt and note payable
Subscriptions pursuant to rights offering, net
|
2019-06-30 |
| 2019-05-15 | 393.90 | 未披露 | 定期报告 | 2019-05-13 |
| 2019-05-15 | 373.18 | 6.29 |
更多>>
from December 31, 2018 to March 31, 2019
Common stock and warrants issued for:
Preferred Unit dividend
|
2019-03-31 |
| 2019-04-01 | 373.18 | 未披露 | 定期报告 | 2019-03-18 |
| 2019-04-01 | 371.54 | 6.29 |
更多>>
from December 31, 2017 to December 31, 2018
Cash proceeds, net
Consulting services
Convertible debt
Prefered Unit dividend
Accrued interest on debt
Shares issued on exercise of warrants
|
2018-12-31 |
| 2018-11-14 | 371.54 | 未披露 | 定期报告 | 2018-11-09 |
| 2018-11-14 | 370.66 | 6.29 | 定期报告 | 2018-09-30 |
| 2018-08-13 | 370.66 | 未披露 | 定期报告 | 2018-08-06 |
| 2018-08-13 | 369.93 | 6.29 | 定期报告 | 2018-06-30 |
| 2018-07-13 | 369.93 | 未披露 | 定期报告 | 2018-06-27 |
| 2018-05-15 | 365.64 | 未披露 | 定期报告 | 2018-05-11 |
| 2018-04-30 | 322.90 | 未披露 | 定期报告 | 2018-04-28 |
| 2018-05-15 | 322.22 | 6.29 | 定期报告 | 2018-03-31 |
| 2018-03-30 | 322.22 | 未披露 | 定期报告 | 2018-03-15 |
| 2018-03-30 | 304.58 | 未披露 |
更多>>
From December 31, 2016 to December 31, 2017
Common stock and warrants issued for:
Cash proceeds, net
Working capital adjustments
Consulting services
Convertible debt
Preferred Unit dividend
Shares released from redemption feature
Round-up shares in reverse split
|
2017-12-31 |
| 2017-11-13 | 302.56 | 未披露 |
更多>>
On October 12, 2017, the Company entered into a Securities Purchase Agreement with institutional and accredited investors in a registered direct offering for the sale of 499,857 shares of common stock (the “Shares”) at a purchase price of $2.00 per share, for a total gross purchase price of $999,714. The Securities Purchase Agreement contains customary representations, warranties and covenants.
|
2017-11-09 |
| 2017-10-24 | 300.04 | 未披露 | 定期报告 | 2017-10-23 |
| 2017-11-13 | 251.42 | 6.29 | 定期报告 | 2017-09-30 |
| 2017-08-14 | 250.05 | 6.29 | 定期报告 | 2017-06-30 |
| 2017-05-19 | 247.43 | 未披露 |
更多>>
On May 17, 2017, Chanticleer Holdings, Inc., a Delaware corporation (the “Company”) filed a certificate of amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-ten reverse stock split of the Company’s shares of common stock.This will be effective for trading purposes as of the commencement of trading on Friday, May 19, 2017.
|
2017-05-19 |
| 2017-05-15 | 2474.30 | 未披露 | 定期报告 | 2017-05-11 |
| 2017-04-19 | 2379.46 | 未披露 | 定期报告 | 2017-04-19 |
| 2017-05-15 | 2214.91 | 6.29 | 定期报告 | 2017-03-31 |
| 2017-03-31 | 2199.95 | 未披露 | 定期报告 | 2017-03-23 |
| 2017-03-31 | 2139.42 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Consulting services
Interest
Reclassification of shares subject to redemption
|
2016-12-31 |
| 2016-08-11 | 2195.71 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-03-31 | 2133.72 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Cash proceeds, net
Business combinations
Consulting services
Convertible debt
Settlement of long-term debt
|
2015-12-31 |
| 2015-12-07 | 2152.22 | 未披露 | 定期报告 | 2015-12-03 |
| 2015-11-16 | 2146.80 | 未披露 | 定期报告 | 2015-11-16 |
From October 1, 2023 to December 11, 2023
Sale of common stock, net of issuance costs
Retirement of shares in connection with reverse stock split
Net share settlement of warrants
Common Stock offered 1,306,250 shares by the company
Sonnet BioTherapeutics Holdings, Inc. announced that it will effect a 1-for-22 reverse stock split of its outstanding common stock.
Common Stock offered 3,660,000 shares by the company
From December 31, 2022 to March 31, 2023
Sale of common stock, net of issuance costs
Issuance of common stock on vesting of restricted stock units
Net share settlement of warrants
Common Stock Offered 11,664,888 shares by the company
From October 1, 2022 to December 31, 2022
Sale of common stock, net of issuance costs
Net share settlement of warrants
From September 30, 2021 to September 30, 2022
Sale of preferred stock and common stock warrants, net of issuance costs
Conversion of preferred stock into common stock
Sale of common stock, net of issuance costs
Issuance of common stock on vesting of restricted stock units
Sonnet BioTherapeutics Holdings, Inc. announced today that it will effect a 1-for-14 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on Monday, September 19, 2022. The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 69.6 million to approximately 5.0 million.
From March 31, 2022 to June 30, 2022
Issuance of common stock on vesting of restricted stock units
From December 31, 2021 to March 31, 2022
Issuance of common stock on vesting of restricted stock units
From September 30, 2020 to September 30, 2021
Sale of common stock and warrants, net of issuance costs
Issuance of common stock on vesting of restricted stock units
Net share settlement of warrants
Warrant exercises
1.Common Stock Offered 33,193,485 shares.
2.The number of shares of common stock that will be outstanding immediately after this offering is based on 24,956,887 shares of common stock outstanding as of August 10, 2021.
From December 31, 2020 To March 31, 2021
Sale of common stock, net of issuance costs
From October 1, 2020 to December 15, 2020
Warrant exercises
Net share settlement of warrants
From September 30, 2019 to September 30, 2020
Sale of common stock and warrants, net of issuance costs
Issuance of common stock to settle related-party notes
Issuance of common stock to affect the Relief acquisition
Issuance of common stock and payment made in connection with Merger
Warrant exercises
from March 31, 2020 to June 30, 2020
Sale of common stock and warrants, net of issuance costs
Issuance of common stock to affect the Relief acquisition
Issuance of common stock and payment made in connection with Merger
In connection with, and immediately prior to the completion of, the Merger, the Company effected a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-26 (the “Reverse Stock Split”).Immediately after the Merger, there were approximately 9.2 million shares of Common Stock outstanding (including 1.1 million Converted Additional Shares (as defined in Item 8.01 of this report) being held in escrow).
from September 30, 2019 to December 31, 2019
Common stock:
Director fees
Preferred Unit dividend
Accrued interest on note payable
Exercise of warrants at reduced price of $0.50
From June 30, 2019 to September 30, 2019
Common stock and warrants issued for:
Preferred Unit dividend
Subscriptions pursuant to rights offering, net
From March 31, 2019 to June 30, 2019
Common stock and warrants issued for:
Director fees
Consulting services
Preferred Unit dividend
Accrued interest on note payable
Share-based compensation
Stock issued to settle convertible debt and note payable
Subscriptions pursuant to rights offering, net
from December 31, 2018 to March 31, 2019
Common stock and warrants issued for:
Preferred Unit dividend
from December 31, 2017 to December 31, 2018
Cash proceeds, net
Consulting services
Convertible debt
Prefered Unit dividend
Accrued interest on debt
Shares issued on exercise of warrants
From December 31, 2016 to December 31, 2017
Common stock and warrants issued for:
Cash proceeds, net
Working capital adjustments
Consulting services
Convertible debt
Preferred Unit dividend
Shares released from redemption feature
Round-up shares in reverse split
On October 12, 2017, the Company entered into a Securities Purchase Agreement with institutional and accredited investors in a registered direct offering for the sale of 499,857 shares of common stock (the “Shares”) at a purchase price of $2.00 per share, for a total gross purchase price of $999,714. The Securities Purchase Agreement contains customary representations, warranties and covenants.
On May 17, 2017, Chanticleer Holdings, Inc., a Delaware corporation (the “Company”) filed a certificate of amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-ten reverse stock split of the Company’s shares of common stock.This will be effective for trading purposes as of the commencement of trading on Friday, May 19, 2017.
from December 31, 2015 to December 31, 2016
Consulting services
Interest
Reclassification of shares subject to redemption
from December 31, 2014 to December 31, 2015
Cash proceeds, net
Business combinations
Consulting services
Convertible debt
Settlement of long-term debt